Genzyme Takes On Sandoz Over Renagel ANDA
The Cambridge, Mass.-based drugmaker filed suit Thursday in the U.S. District Court for the District of Maryland over U.S. Patent Number 5,667,775, which covers both Renagel and Renvela, a second-generation form of the drug.
Renagel and Renvela are nonabsorbed, calcium-free, metal-free phosphate binders used to control serum phosphorus in...
Already a subscriber? Click here to login